Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00533442 · ClinicalTrials.gov registry record · Phase 2
Rapamycin Versus Mycophenolate Mofetil in Kidney-Pancreas Recipients
A Phase 2 study, sponsored by University of Miami.
- Completed
- Registry status
- Phase 2
- Development phase
- 170
- Enrollment target
NCT00533442: Completed Phase 2 study, sponsored by University of Miami.
NCT00533442 is a Phase 2 study that has completed, run by University of Miami. The registered enrollment target is 170 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (28% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00533442, a Phase 2 study, has completed, sponsored by University of Miami.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 170 participants
- Enrollment target
Study Summary
This study was designed to determine which maintenance immunosuppressive agent, rapamycin or mycophenalate mofetil, resulted in better outcome in patients with type 1 diabetes and renal failure, who presented for a kidney-pancreas transplant.
Primary Outcome
Freedom from biopsy-proven acute rejection of the kidney allograft; Freedom from biopsy-proven acute rejection of the pancreas allograft; Death-censored kidney graft survival; Death-censored pancreas graft survival; Death-uncensored graft (kidney and pancreas) survival; and Patient survival.
Interventions
- DRUG Mycophenolate Mofetil
- DRUG Tacrolimus
- DRUG Rapamycin
- DRUG Steroids
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 170 participants |
| Start Date | 2000-09 |
| Est. Completion | 2016-05 |
| Phase | Phase 2 |
What the finished NCT00533442 record still lists
NCT00533442 is an interventional study that assigns participants to a tested intervention. The registered 170 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (28% higher).
The record links to 0 conditions, and to 4 interventions - of which Mycophenolate Mofetil is the first listed.
NCT00533442 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00533442 about?
NCT00533442 is a clinical study titled "Rapamycin Versus Mycophenolate Mofetil in Kidney-Pancreas Recipients". This study was designed to determine which maintenance immunosuppressive agent, rapamycin or mycophenalate mofetil, resulted in better outcome in patients with type 1 diabetes and renal failure, who presented for a kidney-pancreas transplant.
What is the current status of trial NCT00533442?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 170 participants. The study started on 2000-09. Estimated completion is 2016-05.
What interventions are being tested in trial NCT00533442?
The interventions under investigation include: Mycophenolate Mofetil (DRUG), Tacrolimus (DRUG), Rapamycin (DRUG), Steroids (DRUG).
Who is sponsoring clinical trial NCT00533442?
This trial is sponsored by University of Miami, which has 721 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00533442's enrollment target sits among peer trials
170 399th of 2000 higher than 1,598 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02016430 · 170 participants · NA
Gut Flora Metabolite Reduction After Dietary Intervention (GRADY)
- NCT02621021 · 170 participants · Phase 2
A Phase 2 Trial for Metastatic Melanoma Using Adoptive Cell Therapy With Tumor Infiltrating Lymphocytes Plus IL-2 Either Alone or Following the Administration of Pembrolizumab
- NCT04094701 · 170 participants · NA
Hip Arthroscopy Postoperative Opioid Demands
- NCT04166409 · 170 participants · Phase 3
A Study of the Drugs Selumetinib vs. Carboplatin and Vincristine in Patients With Low-Grade Glioma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia